NBY
Price
$0.56
Change
-$0.01 (-1.75%)
Updated
Apr 3 closing price
Capitalization
3.27M
ORMP
Price
$2.16
Change
-$0.04 (-1.82%)
Updated
Apr 3 closing price
Capitalization
87.83M
54 days until earnings call
Ad is loading...

NBY vs ORMP

Header iconNBY vs ORMP Comparison
Open Charts NBY vs ORMPBanner chart's image
NovaBay Pharmaceuticals
Price$0.56
Change-$0.01 (-1.75%)
Volume$45.59K
Capitalization3.27M
Oramed Pharmaceuticals
Price$2.16
Change-$0.04 (-1.82%)
Volume$154.79K
Capitalization87.83M
NBY vs ORMP Comparison Chart
Loading...
NBY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ORMP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NBY vs. ORMP commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NBY is a StrongBuy and ORMP is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (NBY: $0.56 vs. ORMP: $2.16)
Brand notoriety: NBY and ORMP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NBY: 64% vs. ORMP: 53%
Market capitalization -- NBY: $3.27M vs. ORMP: $87.83M
NBY [@Biotechnology] is valued at $3.27M. ORMP’s [@Biotechnology] market capitalization is $87.83M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NBY’s FA Score shows that 0 FA rating(s) are green whileORMP’s FA Score has 0 green FA rating(s).

  • NBY’s FA Score: 0 green, 5 red.
  • ORMP’s FA Score: 0 green, 5 red.
According to our system of comparison, ORMP is a better buy in the long-term than NBY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NBY’s TA Score shows that 3 TA indicator(s) are bullish while ORMP’s TA Score has 3 bullish TA indicator(s).

  • NBY’s TA Score: 3 bullish, 5 bearish.
  • ORMP’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, NBY is a better buy in the short-term than ORMP.

Price Growth

NBY (@Biotechnology) experienced а -7.67% price change this week, while ORMP (@Biotechnology) price change was -6.09% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.91%. For the same industry, the average monthly price growth was -11.19%, and the average quarterly price growth was -14.86%.

Reported Earning Dates

NBY is expected to report earnings on May 11, 2023.

ORMP is expected to report earnings on May 28, 2025.

Industries' Descriptions

@Biotechnology (-8.91% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ORMP($87.8M) has a higher market cap than NBY($3.27M). NBY YTD gains are higher at: -6.439 vs. ORMP (-10.744). ORMP has higher annual earnings (EBITDA): 9.44M vs. NBY (-6.52M). ORMP has more cash in the bank: 142M vs. NBY (776K). ORMP has less debt than NBY: ORMP (429K) vs NBY (1.26M). NBY has higher revenues than ORMP: NBY (13.8M) vs ORMP (0).
NBYORMPNBY / ORMP
Capitalization3.27M87.8M4%
EBITDA-6.52M9.44M-69%
Gain YTD-6.439-10.74460%
P/E RatioN/A20.91-
Revenue13.8M0-
Total Cash776K142M1%
Total Debt1.26M429K294%
FUNDAMENTALS RATINGS
NBY vs ORMP: Fundamental Ratings
NBY
ORMP
OUTLOOK RATING
1..100
5578
VALUATION
overvalued / fair valued / undervalued
1..100
44
Fair valued
68
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10085
PRICE GROWTH RATING
1..100
8256
P/E GROWTH RATING
1..100
10042
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NBY's Valuation (44) in the Biotechnology industry is in the same range as ORMP (68) in the Pharmaceuticals Other industry. This means that NBY’s stock grew similarly to ORMP’s over the last 12 months.

NBY's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ORMP (100) in the Pharmaceuticals Other industry. This means that NBY’s stock grew similarly to ORMP’s over the last 12 months.

ORMP's SMR Rating (85) in the Pharmaceuticals Other industry is in the same range as NBY (100) in the Biotechnology industry. This means that ORMP’s stock grew similarly to NBY’s over the last 12 months.

ORMP's Price Growth Rating (56) in the Pharmaceuticals Other industry is in the same range as NBY (82) in the Biotechnology industry. This means that ORMP’s stock grew similarly to NBY’s over the last 12 months.

ORMP's P/E Growth Rating (42) in the Pharmaceuticals Other industry is somewhat better than the same rating for NBY (100) in the Biotechnology industry. This means that ORMP’s stock grew somewhat faster than NBY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NBYORMP
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
77%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
87%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
81%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
78%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
81%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
84%
Advances
ODDS (%)
Bullish Trend 15 days ago
82%
Bullish Trend 29 days ago
82%
Declines
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 4 days ago
83%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
74%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
83%
View a ticker or compare two or three
Ad is loading...
NBY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ORMP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LTUM0.03N/A
+9.33%
Lithium Corporation.
TLPFY48.78-0.29
-0.59%
Teleperformance
CYDY0.23N/A
-1.95%
CytoDyn Inc.
REPYY12.48-0.61
-4.66%
Repsol S.A.
ADYYF1433.05-134.95
-8.61%
Adyen N.V.

NBY and

Correlation & Price change

A.I.dvisor indicates that over the last year, NBY has been loosely correlated with PRTG. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if NBY jumps, then PRTG could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NBY
1D Price
Change %
NBY100%
-1.70%
PRTG - NBY
38%
Loosely correlated
-13.61%
ALT - NBY
30%
Poorly correlated
-6.69%
ORMP - NBY
29%
Poorly correlated
-1.82%
DARE - NBY
25%
Poorly correlated
+0.69%
IMMP - NBY
25%
Poorly correlated
-3.59%
More

ORMP and

Correlation & Price change

A.I.dvisor indicates that over the last year, ORMP has been loosely correlated with BTAI. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ORMP jumps, then BTAI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ORMP
1D Price
Change %
ORMP100%
-1.82%
BTAI - ORMP
44%
Loosely correlated
-8.54%
INO - ORMP
44%
Loosely correlated
N/A
MBIO - ORMP
44%
Loosely correlated
-9.72%
VERV - ORMP
44%
Loosely correlated
-1.66%
ZNTL - ORMP
43%
Loosely correlated
-7.55%
More